What are the recommended treatments for molluscum contagiosum?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Molluscum Contagiosum Treatment

For symptomatic molluscum contagiosum, physical destruction methods—specifically incision and curettage (aggressive enough to cause bleeding), simple excision with cautery, or cryotherapy—are the recommended first-line treatments, while observation without intervention is appropriate for asymptomatic cases given the self-limited nature of the infection. 1, 2

Treatment Algorithm Based on Clinical Context

For Symptomatic Patients (Cosmetically Bothersome, Ocular Involvement, or Underlying Skin Conditions)

Physical Destruction Methods:

  • Incision and curettage (must be aggressive enough to cause bleeding to be effective)
  • Simple excision with cautery
  • Cryotherapy with liquid nitrogen

These physical modalities are supported by the most recent ophthalmology guidelines (2024) 1 and have been the standard approach across multiple guideline sources. When treating multiple lesions, identify and treat nascent lesions to reduce recurrence risk—reducing viral load allows the host immune response to eliminate residual virus 1, 2.

Important Caveat for Cryotherapy: While effective, cryotherapy carries risk of postinflammatory hyperpigmentation or scarring, particularly in children and patients with darker skin types 3.

For Cosmetically Sensitive Areas or Patients with Eczema

Topical Chemical Treatments:

  • 10% potassium hydroxide (KOH): Demonstrated efficacy with OR 10.02 (95% CI 4.64-21.64) compared to placebo 4
  • Podophyllotoxin: Strong efficacy with OR 10.24 (95% CI 3.36-31.21) 4

Both KOH and cryotherapy show similar efficacy in children 3, making either reasonable depending on patient tolerance and clinical setting.

For Asymptomatic, Immunocompetent Patients

Observation is justified given spontaneous resolution typically occurs in 6-12 months, though complete resolution can take up to 4 years 3. This "watch and wait" approach is explicitly supported by guidelines, particularly in children where physical treatments may be frightening or difficult to perform.

Special Populations

Ocular/Periocular Lesions

Treatment to remove lesions is indicated when symptomatic (causing conjunctivitis or keratitis from viral shedding) 1, 2. The conjunctivitis may require weeks to resolve after lesion elimination. Physical destruction methods remain first-line.

Immunocompromised Patients (HIV, Organ Transplant Recipients)

Large and multiple molluscum lesions with relatively little conjunctival inflammation indicate immunocompromised state 1, 2. These patients develop severe and recalcitrant lesions requiring more aggressive treatment 5. Consider:

  • Cidofovir
  • Imiquimod
  • Interferon

Referral to dermatology is necessary for examination of suspicious lesions 1, 2.

Pregnant Patients

Physical procedures (cryotherapy) are safe 5.

Treatments NOT Recommended

Imiquimod: Not shown to be of benefit compared to placebo in randomized controlled trials 3

Ingenol mebutate: Despite showing the highest efficacy (OR 117.42) in network meta-analysis 4, safety concerns have been reported and it should not be used.

Cantharidin: While open-label studies suggest efficacy, a small randomized controlled trial showed improvement greater than placebo but not statistically significant 3. However, newer standardized preparations (VP-102) show promise in phase III trials 6.

Emerging Treatments

Two experimental topical drugs have shown promising phase III results but are not yet FDA-approved 6:

  • VP-102 (standardized cantharidin preparation)
  • SB206 (berdazimer, topical nitric oxide-releasing product)

These may become first FDA-approved therapies for molluscum contagiosum.

Key Clinical Pitfalls

  1. Don't undertreate multiple lesions: Identify and treat nascent lesions to reduce recurrence—partial treatment allows viral persistence 1, 2

  2. Don't ignore immunocompromised status: Multiple large lesions with minimal inflammation warrant HIV testing and evaluation for immunosuppression 1, 2

  3. Don't use topical antivirals alone: They have not been shown helpful for molluscum (this applies to VZV, not molluscum specifically, but highlights the viral-specific nature of treatments) 1

  4. Consider psychosocial impact: While observation is medically appropriate for asymptomatic cases, the "watch and wait" approach increases transmission risk and can cause anxiety, embarrassment, and isolation—active treatment may be preferred even when not strictly medically necessary 7

  5. Screen for STIs: Patients with genital molluscum should be offered screening for other sexually transmitted infections 5

References

Research

Comparative efficacy of treatments for molluscum contagiosum: A systematic review and network meta-analysis.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2023

Research

2020 European guideline on the management of genital molluscum contagiosum.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2021

Research

New Developing Treatments for Molluscum Contagiosum.

Dermatology and therapy, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.